Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Denosumab Offers Breakthrough in Treatment of Inoperable Giant-Cell Tumour - (DGNews)
    Duloxetine Directly Improves Pain in Patients With Fibromyalgia and Depression: Presented at AAPM - (DGDispatch)
    Intravenous Acetaminophen Reduces Pain, Opioid Consumption After Hip or Knee Surgery: Presented at AAPM - (DGDispatch)
    Methylnaltrexone for Opioid-Induced Constipation Does Not Adversely Affect Pain, Withdrawal Symptoms: Presented at AAPM - (DGDispatch)
    Sodium Oxybate Improves Pain, Function in Patients With Fibromyalgia: Presented at AAPM - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Translating Guidelines Into Practice: An Expert Roundtable Discussion of Optimal Antiplatelet Therapy in Acute Coronary Syndrome
    • Current State of the Art in Antiplatelet Therapy in Clinical Practice: Results From the Field
    • The Future of Antiplatelet Therapy in Patients With ACS: Can We See it From Here?
    • Tools for Supporting Optimal Fibromyalgia Diagnosis and Treatment: An Update for Primary Care and Managed Care
      Deep Vein Thrombosis in Focus: Expert Perspectives on Reducing the Burden of Venous Thromboembolism

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        The Influence Of Hepatitis C Infection And Interferon-alpha Therapy On Thyrotropin Blocking And Stimulating Autoantibodies In Graves' Ophthalmopathy: A Case Report
        Sigma-1 Receptor Agonist Fluvoxamine For Delirium In Patients With Alzheimer's Disease
        Olanzapine And Pulmonary Embolism, A Rare Association: A Case Report
        Anti-Inflammatory Effects Of Antidepressant And Atypical Antipsychotic Medication For The Treatment Of Major Depression And Comorbid Arthritis: A Case Report
        Etanercept And Venous Thromboembolism: A Case Series

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Advair Inhalers Safe in a Twice-Daily Regimen for Adult Asthmatics: Presented at ACCP

        By Maria Bishop

        BOSTON, MA -- September 18, 2006 -- The combination of inhaled fluticasone propionate and salmeterol (Advair) appears to be safe for adults with asthma who require a twice-daily regimen, according to investigators speaking here at the American College of Clinical Pharmacology 35th Annual Meeting (ACCP).

        Thirteen adult asthmatics completed a randomized, double-blind, placebo-controlled, repeat-dose, 4-way crossover study comparing the pharmacokinetics and systemic pharmacodynamics of fluticasone and salmeterol for 4 weeks.

        Systemic exposure to fluticasone propionate from Advair DISKUS (a combination fluticasone propionate and salmeterol dry-powder inhaler) and Advair metered-dose inhaler (a formulation of the 2 drugs administered by hydrofluoroalkane [HFA] propellant) was similar and did not affect serum cortisol levels at therapeutic doses (250/50 mcg twice daily for the DISKUS and 125/25 mcg twice daily for the metered-dose inhaler). By comparison, fluticasone systemic exposure from a similar drug--Flovent HFA metered-dose inhaler (2 inhalations of 125 mcg twice daily)--was lower than exposure from the Advair inhalers, and also did not affect serum cortisol.

        Salmeterol systemic exposure was again similar in the Advair DISKUS and metered-dose-inhaler groups, and did not produce any significant increases in heart rate or QTc interval assessments compared with placebo, said lead investigator Rashmi Mehta, senior pharmacokineticist, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina.

        No correlations were found between fluticasone propionate and salmeterol pharmacodynamic effects and exposure, and both treatments were well tolerated, with no serious adverse effects observed in the twice-daily regimen.

        The researchers concluded that the repeat-dose regimen used in this study appears safe for use by adult asthmatics.


        [Presentation title: Pharmacokinetics and Pharmacodynamics of Inhaled Advair (Fluticasone Propionate/Salmeterol) DISKUS and Metered-Dose Inhalers in Adult Patients with Asthma. Abstract 38]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send